



**DRAFT**

# NorCal SOT & PBSS Spring Symposium 2018

## Immuno-oncology: Opportunities, Therapeutic Approaches, and Safety Considerations

*April 27, 2018*

*South San Francisco Conference Center, 255 South Airport Boulevard,  
South San Francisco, CA 94080*

<b>Morning Session</b>	
7:30 am – 8:30 am	<b>Registration &amp; Breakfast</b>
8:30 am – 8:45 am	<b>Opening Messages from the NorCal SOT &amp; PBSS Presidents</b> <i>Doris Zane, PhD, DABT, Senior Director, Preclinical Development, Intarcia Therapeutics, Inc.</i> <i>Shichang Miao, PhD, Vice President, Preclinical Development and Clinical DMPK, ChemoCentryx Inc.</i>
8:45 am – 9:25 am	<b>Presentation 1: A Brief History of Immunotherapy</b> <i>Keith Bahjat, PhD, Director, Bristol-Myers Squibb</i>
9:25 am – 10:10 am	<b>Presentation 2: Immune-Oncology: Nonclinical Challenges</b> <i>Haleh Saber, PhD, Deputy Director, Division of Hematology Oncology Toxicology, FDA</i>
10:10 am – 10:25 am	<b>Coffee Break</b>
10:25 am – 10:50 am	<b>NorCal Student Award presentation: Influence of Genetic Background on Polychlorinated Biphenyl (PCB) Developmental Neurotoxicity</b> <i>Sunjay Sethi, Graduate Student, University of California Davis</i>
10:50 am – 11:30 am	<b>Presentation 3: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model</b> <i>Henry QX Li, PhD, Senior Vice President, Global Scientific Research and Innovation Division, Crown Bioscience</i>
11:30 am – 12:10 pm	<b>Presentation 4: Title TBD (Topic – Preclinical development – animal models for selecting/optimizing drug candidates)</b> <i>Greg Bannish, PhD, Vice President, Biopharmaceutical Development, Envigo</i>
12:10 pm – 1:40 pm	<b>Lunch Break: <a href="#">Lunch with Experts, Posters</a></b>
<b>Afternoon Session</b>	
1:40 pm – 1:55 pm	<b>Chapter Announcements and Acknowledgements</b>
1:55 pm – 2:35 pm	<b>Presentation 5: Nonclinical Safety Challenges for Cancer Immunotherapeutics</b> <i>Rodney Prell, PhD, DABT, Principal Scientist/Toxicologist, Genentech</i>
2:35 pm – 3:15 pm	<b>Presentation 6: Nonclinical Safety Assessment of CARTs: A Multipronged Approach</b> <i>Herve Lebec, PhD, DABT, Scientific Director, Amgen Inc.</i>
3:15 pm – 3:30 pm	<b>Coffee Break</b>
3:30 pm – 4:00 pm	<b>Presentation 7: Microbiome Research as an Innovative Platform for Biomarker and Drug Discovery</b> <i>Allyson Byrd, Phd, Genentech</i>
4:00 pm – 4:05 pm	<b>Closing Remarks</b>
4:05 pm – 5:00 pm	<b>Reception &amp; Networking</b>

**[DIRECTIONS TO SSF CONFERENCE CENTER](#)**